GeNeuro announces the results of the GNC-501 trial in post-Covid-19 syndrome

GeNeuro announced results from the GNC-501 clinical trial, a Phase 2 study involving 200 patients in Switzerland, Spain and Italy, testing temelimab versus placebo for post-COVID-19 neuropsychiatric syndromes. Initial results did not show a clinically significant improvement compared to placebo on the primary endpoint of fatigue. The majority of secondary endpoints showed no effect. However, the treatment was well tolerated and safe.

Preliminary analyzes suggest that disease duration at baseline and change in HERV-W ENV status may influence efficacy measures. GeNeuro will continue to analyze the full data as it becomes available.

Following these results, the board of directors decided to reduce its costs and its workforce to preserve its cash flow. Seven out of nine employees, including management, were laid off. A strategic plan will be announced soon.

The company will look for ways to add value to its assets in development against multiple sclerosis and amyotrophic lateral sclerosis, as well as its HERV platform.